$-0.03
(Market cap
$4 Mln
Revenue (TTM)
$45 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-36 Mln
-
ROE
-17.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0.3
-
Book Value
$2.4
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
6,080,920
10 Years Aggregate
CFO
$-356.83 Mln
EBITDA
$-366.34 Mln
Net Profit
$-427.83 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Redhill Biopharma - ADR
| -32.5 | 14.9 | -32.5 | -51.5 | -89.1 | -92.2 | -73.3 |
|
BSE Sensex
| -10.7 | -3.7 | 1.8 | -6.4 | 4.5 | 5.3 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Redhill Biopharma - ADR
| -83.4 | -99.3 | -74.0 | -94.6 | -68.1 | 33.1 | 9.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Redhill Biopharma - ADR
|
0.7 | 4.4 | 0.3 | -0.4 | -30.0 | 206.7 | -- | 1.2 |
| 17.2 | 6,074.3 | 3,117.6 | 157.4 | 14.7 | -- | 36.3 | 188.5 | |
| 208.2 | 10,826.1 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 131.0 | |
| 74.3 | 14,630.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 114.7 | 12,065.9 | 830.8 | 54.9 | 3.2 | 8.1 | 248 | 17.3 | |
| 11.9 | 10,020.9 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 29.3 | 2.5 | |
| 24.0 | 12,236.5 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.9 | |
| 287.2 | 5,693.6 | 290.5 | 197.2 | 82.5 | 19.9 | 29.8 | 5.9 | |
| 67.4 | 6,145.7 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 30.7 | |
| 128.8 | 8,210.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 19.0 |
Shareholding Pattern
View DetailsAbout Redhill Biopharma - ADR
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the... treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel. Read more
-
Co-Founder, Chairman & CEO
Mr. Dror Ben-Asher
-
Co-Founder, Chairman & CEO
Mr. Dror Ben-Asher
-
Headquarters
Tel Aviv-Yafo
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Redhill Biopharma - ADR
What is the current share price of Redhill Biopharma Ltd - ADR Today?
The share price of Redhill Biopharma Ltd - ADR is $0.69 (NASDAQ) as of 08-Sep-2026 14:37 EDT. Redhill Biopharma Ltd - ADR has given a return of -89.11% in the last 3 years.
What is the current PB & PE ratio of Redhill Biopharma Ltd - ADR?
Since, TTM earnings of Redhill Biopharma Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.33 |
0.44 |
2024 |
-1.94 |
-3.42 |
2023 |
0.03 |
0.39 |
2022 |
0.00 |
0.00 |
2021 |
0.00 |
0.03 |
What is the 52 Week High and Low of Redhill Biopharma Ltd - ADR?
The 52-week high and low of Redhill Biopharma Ltd - ADR are Rs 2.79 and Rs 0.57 as of 09-Sep-2026.
What is the market cap of Redhill Biopharma Ltd - ADR?
Redhill Biopharma Ltd - ADR has a market capitalisation of $ 4 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Redhill Biopharma Ltd - ADR?
Before investing in Redhill Biopharma Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.